Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5179 - Prognostic Importance of Lymph Node (LN) yield after Curative Resection of GastroEnteroPancreatic NeuroEndocrineTumours (GEP NETs)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Pathology/Molecular Biology;  Surgical Oncology

Tumour Site

Neuroendocrine Neoplasms

Presenters

Jaseela Chiramel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

J. Chiramel1, R. Almond2, A.E. Slagter3, A. Khan1, K.H.J. Lim1, B. Chakrabarty4, A. Minicozzi5, A. Lamarca6, W. Mansoor1, R. Hubner1, J.W. Valle6, M.G. McNamara1

Author affiliations

  • 1 Medial Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Analytics And Development, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 3 Radiation oncology, NKI-AVL, 1066 CX - Amsterdam/NL
  • 4 Pathology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 5 Surgery, The Christie Hospital NHS Foundation Trust, M20 4BX - Manchester/GB
  • 6 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
More

Abstract 5179

Background

Surgery is the main stay of treatment for GEP NETs, but there is no consensus on optimal number of resected LNs. The effect of LN status and yield on relapse-free (RFS) and overall survival (OS) in patients (pts) with resected GEP NETs were evaluated.

Methods

Data on pts who underwent curative resection for GEP-NETs (Jan 02-Mar 17) were retrospectively analysed. Grade III tumours (Ki67>20%) were excluded. Kaplan-Meier and univariate/multivariable Cox-proportional hazard analyses were performed. Cut-point analysis was assessed to distinguish a binary categorisation of total LNs retrieved associated with RFS.

Results

Of 217 pts, median (med) age was 59 yrs: 51% male. Primary tumour sites: small bowel (42%), pancreas (25%), appendix (18%), rectum (7%), colon (3%), gastric (2%), others (2%); grade 1 (G1): 77%, G2: 23%. LN cut-point value associated with RFS was 8; ≥8 LNs were retrieved in 106 pts, <8 in 45, and 0 or no record/documentation of LN retrieval in 66. Relapse was reported in 50 pts; 35 deaths. Med follow up times for all pts were 41 months (95% CI 36-51) and 71 months (95% CI 63–76) for RFS and OS respectively. On univariate analysis, there was no effect of LN ratio (number involved/number retrieved) on RFS: p = 0.1 or OS: p = 0.75. On univariate analysis, tumour necrosis (p = 0.021) and perineural infiltration (p = 0.016) were the only two variables significantly associated with OS; G (p = 1), TNM staging (p = 0.19) and surgical margin (p = 0.69) were not significantly associated with OS. Multivariable analysis for RFS included 4 variables of interest: perineural infiltration, LNs retrieved, positive LNs and localisation (Table).Table: 1325P

VariableHazard Ratio(95% CI)p
Perineural infiltration1.46(0.74 - 2.69)0.277
≥8 lymph nodes retrieved2.70(1.07 - 6.84)0.036
Any lymph nodes positive2.71(0.88 - 8.30)0.081
Pancreas (relative to 'other')27.33(2.54 - 294.08)0.006
Small Bowel (relative to 'other')32.44(2.92 - 360.58)0.005

Conclusions

Removal of ≥ 8 LNs is associated with greater risk of relapse in G1 & G2 GEP NETs; localisation also has a significant association with RFS, necessitating stricter surveillance. Larger prospective studies are required to validate these findings.

Clinical trial identification

Legal entity responsible for the study

The Christie Hospital NHS Trust, Manchester, Uk.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.